rs746087148
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_002691.4(POLD1):c.946G>A(p.Asp316Asn) variant causes a missense change. The variant allele was found at a frequency of 0.00000125 in 1,596,166 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_002691.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLD1 | NM_002691.4 | c.946G>A | p.Asp316Asn | missense_variant | Exon 8 of 27 | ENST00000440232.7 | NP_002682.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152262Hom.: 0 Cov.: 33
GnomAD4 exome AF: 6.93e-7 AC: 1AN: 1443904Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 714794
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152262Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74380
ClinVar
Submissions by phenotype
not provided Uncertain:1
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies suggest a damaging effect: defective DNA mismatch repair (Murphy et al., 2006; Fazlieva et al., 2009); Identified in patients with colorectal or endometrial cancer, co-occurring with a PMS2 deletion in one family (Robinson et al., 2021; Palles et al., 2022; Schamschula et al., 2022); This variant is associated with the following publications: (PMID: 25228659, 33948826, 8987997, 1989882, 34875102, 20951805, 34594041, 19282447, 16699561, 36291559) -
Colorectal cancer, susceptibility to, 10 Uncertain:1
This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 316 of the POLD1 protein (p.Asp316Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with colorectal adenomas and/or endometrial cancer (PMID: 33948826). ClinVar contains an entry for this variant (Variation ID: 246506). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt POLD1 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects POLD1 function (PMID: 19282447). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.D316N variant (also known as c.946G>A), located in coding exon 7 of the POLD1 gene, results from a G to A substitution at nucleotide position 946. The aspartic acid at codon 316 is replaced by asparagine, an amino acid with highly similar properties. In one study, the exonuclease activity of a POLD1 double mutant, p.D316N/D515A, was decreased by more than 95% compared to wild-type; however, this alteration was found to have lower lesion-bypass activity than wild-type, suggesting that the proofreading function is maintained. It is unclear whether the functional effects reported in this assay can be attributed to D316N or D515A, or if there is a synergistic effect (Fazlieva R et al. Nucleic Acids Res, 2009 May;37:2854-66). This alteration has been identified in an individual diagnosed with serrated polyps (Murphy A et al. J Gastroenterol Hepatol, 2022 May;37:861-869). This alteration was also identified in an individual diagnosed with multiple primary colorectal cancers and ureter cancer; however, was also identified to carry a pathogenic PMS2 alteration (Schamschula E et al. Biomolecules, 2022 Sep;12:). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at